The cell and gene therapy (CGT) market is poised to witness a significant upsurge, and is expected to grow from USD 25.03 billion in 2025 to around USD 117.46 billion by 2034. This reflects a compound annual growth rate of 18.7 percent. Furthermore, this expansion is driven by factors such as the rising number of regulatory approvals, technological advancements, and increased investments in research and development. Also to note, the diversification of therapy applications encompasses beyond oncology, so as to address a wider range of diseases, today.

With this burgeoning trajectory, startups will play a pivotal role in advancing the CGT landscape by driving innovation and addressing unmet medical needs. The startups’ agility can allow for rapid development and adaptation of novel therapies, particularly for rare and complex diseases. For instance, a groundbreaking case involved a customized CRISPR treatment developed for a baby with a rare genetic liver disorder, showcasing the potential of personalized medicine. Such endeavors highlight how startups can pioneer treatments that may not be immediately pursued by larger pharmaceutical companies due to scale or risk considerations.

Adding to this, startups also contribute to the broader pharmaceutical ecosystem by fostering collaborations and partnerships. These players often engage in licensing agreements and joint ventures with established firms, facilitating the translation of innovative research into commercially viable therapies. Additionally, manufacturing startups provide cost-efficient production solutions, enabling smaller biotech companies to focus on research while ensuring scalable and compliant manufacturing processes. Through these collaborative efforts, startups not only accelerate the development of CGTs but also enhance the overall efficiency and responsiveness of the pharmaceutical industry. EFB Public

Understanding the importance of startups in bolstering CGT market further, India Pharma Outlook brings to you a meticulously crafted monthly edition focusing on - ‘TOP 10 Startups in Cell and Gene Therapy.’ Our editorial team and industry experts have thoroughly scrutinized numerous startups to select upon a few who bring proven track records in driving the needed innovation in the realm of cell and gene therapy. We will shed light on these players’ promising journey, product portfolios, USPs, milestones and future roadmap.